Minimizing morbidity of hypoglycemia in diabetes: A review of mini-dose Glucagon

Journal of Diabetes Science and Technology

Volumn 9, Issue 1, 2015, Pages 44-51

  Chung, Stephanie T ^a   Haymond, Morey W ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

hypoglycemia; insulin Treated diabetes; subcutaneous; type 1 diabetes

Indexed keywords

GLUCAGON; GLUCOSE; GLUCOSE BLOOD LEVEL;

ARTICLE; DIABETES MELLITUS; DRUG MECHANISM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OFF LABEL DRUG USE; ADULT; CHILD; DIABETES MELLITUS, TYPE 1; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MORBIDITY; SECRETION (PROCESS); SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON; HUMANS; HYPOGLYCEMIA; INJECTIONS, SUBCUTANEOUS; MORBIDITY;

EID: 84947923764     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296814547518     Document Type: Article

References (85)

1. Cryer PE. Hypoglycemia-The limiting factor in the management of iddm. Diabetes. Nov 1994;43(11):1378-1389.
2. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of type i and type ii diabetes. Diabetologia. Jul 2002;45(7):937-948.
3. Hepburn DA, MacLeod KM, Pell AC, Scougal IJ, Frier BM. Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabetic Med. Apr 1993;10(3):231-237.
4. Maltoni G, Zucchini S, Scipione M, et al. Severe hypoglycemic episodes: A persistent threat for children with Type 1 diabetes mellitus and their families. J Endocrinol Invest. Sep 2013;36(8):617-621.
5. Cengiz E, Xing D, Wong JC, et al. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D exchange clinic registry. Pediatr Diabetes. Sep 2013;14(6):447-454.
6. Cengiz E, Connor CG, Ruedy KJ, et al. Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis. Pediatr Diabetes. Jun 2014;15(4):287-293.
7. Weinstock RS, Xing D, Maahs DM, et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab. Aug 2013;98(8):3411-3419.
8. Aman J, Wranne L. Hypoglycaemia in childhood diabetes. I. Clinical signs and hormonal counterregulation. Acta Paediatrica Scandinavica. Jul 1988;77(4):542-547.
9. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. Sep 2012;35(9):1897-1901.
10. MacLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycaemia in insulin-Treated diabetic patients. Diabetic Med. Apr 1993;10(3):238-245.
11. Brodovicz KG, Mehta V, Zhang Q, et al. Association between hypoglycemia and inpatient mortality and length of hospital stay in hospitalized, insulin-Treated patients. Curr Med Res Opin. Feb 2013;29(2):101-107.
12. Cryer PE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care. Sep 2012;35(9):1814-1816.
13. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use. Diabetes Care. Apr 2003;26(4):1176-1180.
14. Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: An overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14(5):646-655.
15. Rombopoulos G, Hatzikou M, Latsou D, Yfantopoulos J. The prevalence of hypoglycemia and its impact on the quality of life (QoL) of type 2 diabetes mellitus patients (the HYPO Study). Hormones (Athens). Oct-Dec 2013;12(4):550-558.
16. Hoffman RP, Arslanian S, Drash AL, Becker DJ. Impaired counterregulatory hormone responses to hypoglycemia in children and adolescents with new onset IDDM. J Pediatr Endocrinol. Jul-Sep 1994;7(3):235-244.
17. Liu DT, Adamson UC, Lins PE, Kollind ME, Moberg EA, Andreasson K. Inhibitory effect of circulating insulin on glucagon secretion during hypoglycemia in type I diabetic patients. Diabetes Care. Jan 1992;15(1):59-65.
18. Sjoberg S, Ahren B, Bolinder J. Residual insulin secretion is not coupled to a maintained glucagon response to hypoglycaemia in long-Term type 1 diabetes. J Int Med. Oct 2002;252(4):342-351.
19. Liu D, Adamson U, Lins PE, Clausen-Sjobom N. An analysis of the glucagon response to hypoglycaemia in patients with type 1 diabetes and in healthy subjects. Diabetic Med. Apr 1993;10(3):246-254.
20. Cryer PE. Mechanisms of hypoglycemia-Associated autonomic failure and its component syndromes in diabetes. Diabetes. Dec 2005;54(12):3592-3601.
21. Bulsara MK, Holman CD, Davis EA, Jones TW. The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes. Diabetes Care. Oct 2004;27(10):2293-2298.
22. Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care. Jan 1997;20(1):22-25.
23. Rewers A, Chase HP, Mackenzie T, et al. Predictors of acute complications in children with type 1 diabetes. JAMA. May 2002;287(19):2511-2518.
24. Clarke W, Jones T, Rewers A, Dunger D, Klingensmith GJ. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. Sep 2009;10(suppl 12):134-145.
25. Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care. 2001;24(4):643-645.
26. Brink S, Laffel L, Likitmaskul S, et al. Sick day management in children and adolescents with diabetes. Pediatr Diabetes. Sep 2009;10(suppl 12):146-153.
27. Murlin J, Clough HD, Gibbs CBF, Stokes AM. Aqueous extracts of pancreas. I influence on the carbohydrate metabolism of depancreatized animals. J Biol Chem. 1923;56: 253-296.
28. Bromer W, Staub A, Diller ER, Bird HL, Sinn LG, Behrens OK. The amino acid sequence of glucagon. i. amino acid composition and terminal amino acid analyses. 1957. 1956 79 11 2794-2798.
29. Sutherland EaDDC. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. J Biol Chem. 1948;175:663-674.
30. Carson MJ, Koch R. Clinical studies with glucagon in children. J Pediatr. Aug 1955;47(2):161-170.
31. Vukmir RB, Paris PM, Yealy DM. Glucagon: prehospital therapy for hypoglycemia. Ann Emerg Med. Apr 1991;20(4): 375-379.
32. Kedia N. Treatment of severe diabetic hypoglycemia with glucagon: An underutilized therapeutic approach. Diabetes Metab Syndrome Obes. 2011;4:337-346.
33. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm?fuseaction=Search.DrugDetails. Accessed July 11, 2014.
34. Tse TF, Clutter WE, Shah SD, Cryer PE. Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-A-vis insulin in the prevention of hypoglycemia late after glucose ingestion. J Clin Invest. 1983;72(1):278-286.
35. Ahren B, Nobin A, Schersten B. Insulin and C-peptide secretory responses to glucagon in man: studies on the dose-response relationships. Acta Medica Scandinavica. 1987;221(2):185-190.
36. Rizza RA, Cryer PE, Gerich JE. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha-And beta-Adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest. Jul 1979;64(1):62-71.
37. Cryer PE. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. Mar 2012;153(3):1039-1048.
38. Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science. Oct 1973;182(4108):171-173.
39. Bolli G, de Feo P, Compagnucci P, et al. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes. Feb 1983;32(2):134-141.
40. Ferrannini E, DeFronzo RA, Sherwin RS. Transient hepatic response to glucagon in man: role of insulin and hyperglycemia. Am J Physiol. 1982;242(2):E73-E81.
41. Unger RH. Role of glucagon in the pathogenesis of diabetes: The status of the controversy. Metab Clin Exp. Nov 1978;27(11):1691-1709.
42. Gerich J, Davis J, Lorenzi M, et al. Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol. Apr 1979;236(4):E380-385.
43. Rizza R, Verdonk C, Miles J, Service FJ, Gerich J. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man. J Clin Invest. Jun 1979;63(6):1119-1123.
44. Rizza RA, Gerich JE. Persistent effect of sustained hyperglucagonemia on glucose production in man. J Clin Endocrinol Metab. Feb 1979;48(2):352-355.
45. Kaplan W, Sunehag AL, Dao H, Haymond MW. Short-Term effects of recombinant human growth hormone and feeding on gluconeogenesis in humans. Metab Clin Exp. Jun 2008;57(6):725-732.
46. Tigas S, Sunehag A, Haymond M. Metabolic adaptation to feeding and fasting during lactation in humans. J Clin Endocrinol Metab. 2002;87(1):302-307.
47. Cherrington AD, Williams PE, Shulman GI, Lacy WW. Differential time course of glucagons effect on glycogenolysis and gluconeogenesis in the conscious dog. Diabetes. 1981;30(3):180-187.
48. Gosmanov NR, Szoke E, Israelian Z, et al. Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans. Diabetes Care. May 2005;28(5): 1124-1131.
49. Raju B, Cryer PE. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans. Diabetes. Mar 2005;54(3):757-764.
50. Raju B, Cryer PE. Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? Am J Physiol Endocrinol Metab. Aug 2005;289(2):E181-186.
51. Banarer S, McGregor VP, Cryer PE. Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes. Apr 2002;51(4):958-965.
52. Kawamori D, Kurpad AJ, Hu J, et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab. Apr 2009;9(4):350-361.
53. Vermeulen M, Klompas M, Ray J, Mazza C, Morrison L. Subcutaneous glucagon may be better than oral glucose for prehospital treatment of symptomatic hypoglycemia. Diabetes Care. 2003;26(8):2472-2473.
54. Pagliara AS, Kari IE, De Vivo DC, Feigin RD, Kipnis DM. Hypoalaninemia: A concomitant of ketotic hypoglycemia. J Clin Invest. 1972;51(6):1440-1449.
55. Rizza R, Verdonk C, Miles J, Service FJ, Haymond M, Gerich J. Somatostatin does not cause sustained fasting hyperglycemia in man. Horm Metab Res. Nov 1979;11(11):643-644.
56. Service FJ, Rizza RA, Gerich JE. Infusion-pump treatment of diabetes mellitus. N Engl J Med. Aug 1979;301(5):267-268.
57. Felig P, Tamborlane W, Sherwin RS, Genel M. Insulininfusion pump for diabetes. N Engl J Med. Nov 1979;301(18): 1004-1005.
58. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med. Mar 1979;300(11):573-578.
59. Hartley M, Thomsett MJ, Cotterill AM. Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: The Brisbane experience. J Paediatr Child Health. Mar 2006;42(3):108-111.
60. Committee CDACPGE. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2013;37(1): S1-S212.
61. http://www.hamiltonhealthsciences.ca/documents/Patient% 20Education/GlucagonMiniDose-lw.pdf. Accessed May 24, 2014.
62. http://www.childrenwithdiabetes.com/d-0j-20w.htm. Accessed May 24, 2014.
63. www.nationwidechildrens.org. Accessed May 24, 2014.
64. www.seattlechildrens.org/pdf/PE566.pdf. Accessed May 24, 2014.
65. www.schn.health.nsw.gov.au/policies/pdf/2010-8034.pdf. Accessed May 24, 2014.
66. http://www.rch.org.au/uploadedFiles/Main/Content/diabetes/Minidose%20Glucagon%20Guideline%20glucagon%20rescue. pdf. Accessed May 24, 2014.
67. http://www.fvfiles.com/521147.pdf. Accessed May 24, 2014.
68. http://www.bcchildrens.ca/NR/rdonlyres/8954ADE9-2B5B-45-24-9715-93F1E0CD5ED0/64812/minigluc.pdf. Accessed May 24, 2014.
69. http://www.uwhealth.org/healthfacts/pediatric-diabetes/7481. pdf. Accessed May 24, 2014.
70. http://www.hoteldieu.com/dec/MinidoseGlucagonProtocol. pdf. Accessed May 24, 2014.
71. http://www.health.qld.gov.au/caru/networks/docs/parentsguide. pdf. Accessed May 24, 2014.
72. http://diabetes.ucsf.edu/sites/diabetes.ucsf.edu/files/Sick% 20Day%20Final%2011%2023%2009-0.pdfhwjofp. Accessed May 24, 2014.
73. www.adea.com.au/wp-content/uploads/2013/08/sickday- sum-mary.pdf. Accessed May 24, 2014.
74. http://www.childrensmn.org/images/PDF/diabetesmanual.pdf. Accessed May 24, 2014.
75. http://choosehealth.utah.gov/documents/dpr/udpr-section4-children-sep07.pdf. Accessed May 24, 2014.
76. Hasan KS, Kabbani M. Mini-dose glucagon is effective at diabetes camp. J Pediatr. Jun 2004;144(6):834.
77. Busselo J, Domino AJ, Marra EM. Mini-dose of glucagon: great efficacy avoiding admission of insulin-dependent-diabetic children with decreasing normoglycemia or hypoglycemia due to vomiting or gastroenteritis. Pediatr Res. 2010;68:363-364.
78. Staub AaB, OK. The glucagon content of crystalline insulin preparations. J Clin Invest. 1954;33(12):1629-1633.
79. Onoue S, Iwasa S, Kojima T, et al. Structural transition of glucagon in the concentrated solution observed by electrophoretic and spectroscopic techniques. J Chromatogr A. 2006;1109(2):167-173.
80. Onoue S, Ohshima K, Debari K, et al. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res. 2004;21(7):1274-1283.
81. Elliott J, Jacques RM, Kruger J, et al. Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with Type 1 diabetes. Diabetic Med. Jul 2014;31(7):847-853.
82. Pontiroli AE, Calderara A, Pajetta E, Alberetto M, Pozza G. Intranasal glucagon as remedy for hypoglycemia. Studies in healthy subjects and type I diabetic patients. Diabetes Care. Oct 1989;12(9):604-608.
83. Stenninger E, Aman J. Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. Oct 1993;36(10):931-935.
84. Rosenfalck AM, Bendtson I, Jorgensen S, Binder C. Nasal glucagon in the treatment of hypoglycaemia in type 1 (insulin-dependent) diabetic patients. Diabetes Res Clin Pract. Jul 1992;17(1):43-50.
85. Pontiroli AE, Calderara A, Pozza G. Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective. Clin Pharmacokinet. Nov 1989;17(5):299-307.